Advertisement
AMGN vs MRK
Which Stock Would AI Choose? Amgen (AMGN) vs. Merck (MRK) Stock Comparison
Key Takeaways
- Merck (MRK) has delivered stronger year-to-date performance with approximately 25.5% return through late July 2026, outpacing broader market benchmarks amid pipeline advancements.
- Amgen (AMGN) maintains a diversified biotechnology portfolio focused on oncology, inflammation, and cardiovascular therapies, with performance influenced by clinical data readouts and sector rotation in recent market activity.
- Merck (MRK) benefits from multiple positive analyst revisions and upcoming earnings, supported by Keytruda dominance and new product approvals such as the oral PCSK9 inhibitor.
- Both companies operate in the healthcare sector with exposure to regulatory and competitive risks, though Merck (MRK) shows more pronounced recent momentum in oncology and HIV pipelines.
- Relative positioning favors stability in established franchises for Merck (MRK), while Amgen (AMGN) offers potential in biosimilars and emerging modalities.
- Market sentiment reflects broader healthcare trends, with both stocks reacting to earnings guidance and clinical trial updates over recent weeks.
Introduction
This comparison examines Amgen (AMGN) and Merck (MRK), two prominent healthcare stocks, to highlight differences in business models, recent performance drivers, and market positioning. Investors and traders focused on the biotechnology and pharmaceutical sectors may find the analysis relevant when evaluating relative value, momentum, and risk profiles within large-cap healthcare. The review draws on observable price behavior, analyst activity, and pipeline developments to provide a factual basis for understanding how these names have responded in the current environment.
Amgen Overview and Recent Performance
Amgen (AMGN) is a leading biotechnology company with a portfolio centered on innovative therapies in oncology, inflammation, and cardiovascular disease. In recent market activity, the stock has reflected broader sector dynamics, including responses to clinical trial updates and competitive pressures in key therapeutic areas. Performance has been shaped by ongoing biosimilar competition and pipeline progress, with sentiment influenced by earnings commentary and macroeconomic factors affecting healthcare valuations. Over recent weeks, Amgen (AMGN) has navigated volatility typical of the biotech space while maintaining focus on long-term growth through research and development initiatives.
Merck Overview and Recent Performance
Merck (MRK) is a global pharmaceutical company known for its strength in oncology, vaccines, and animal health. The stock closed at $130.20 on July 31, 2026, delivering a year-to-date return of 25.51%. Recent market activity has been supported by pipeline advancements, including positive data in HIV prevention and oncology combinations, as well as FDA clearance for new products such as Lipfendra, an oral PCSK9 cholesterol pill. Analyst sentiment has remained constructive, with several price target increases ahead of the Q2 earnings release scheduled for August 4. Broader momentum reflects robust sales from established franchises like Keytruda and contributions from recent launches.
Trending AI Robots
Tickeron maintains a curated section highlighting its most suitable AI trading bots for prevailing market conditions. While hundreds of AI trading bots are available across thousands of tickers, only those demonstrating strong alignment with current trends, risk parameters, and performance metrics are featured in the Trending AI Robots section. These bots employ varied strategies, timeframes, and statistical profiles, allowing users to explore options suited to different trading styles. Performance ranges and historical statistics are transparently displayed for each bot to aid evaluation. Trending AI Robots
Head-to-Head Comparison
Amgen (AMGN) operates primarily as a biotechnology innovator with emphasis on complex biologics and targeted therapies, while Merck (MRK) combines large-scale pharmaceutical commercialization with a robust late-stage pipeline. Growth drivers differ, with Merck (MRK) leveraging Keytruda’s established market position and recent approvals, contrasted against Amgen (AMGN)’s focus on biosimilar erosion management and emerging assets. Recent momentum has favored Merck (MRK) through consistent analyst upgrades and clinical catalysts, whereas Amgen (AMGN) has shown more measured responses tied to sector-wide healthcare rotation. Risk factors include patent cliffs and regulatory scrutiny for both, though Merck (MRK) exhibits greater sector exposure via diversified franchises. Market sentiment currently tilts toward Merck (MRK)’s visibility in near-term catalysts relative to Amgen (AMGN)’s longer development cycles.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent analyst revisions, and pipeline visibility, Tickeron’s AI would currently assign a higher probabilistic preference to Merck (MRK). The stock’s demonstrated momentum in oncology and new product launches, alongside constructive price target adjustments, provide a clearer near-term positioning compared with Amgen (AMGN)’s more variable biotech-driven profile. This assessment remains probabilistic and tied to prevailing data rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- MRK’s TA Score: 3 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +6.69% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.16%. For the same industry, the average monthly price growth was +0.25%, and the average quarterly price growth was +3.08%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | MRK | AMGN / MRK | |
| Capitalization | 222B | 318B | 70% |
| EBITDA | 16.7B | 19.4B | 86% |
| Gain YTD | 27.377 | 23.944 | 114% |
| P/E Ratio | 25.52 | 102.86 | 25% |
| Revenue | 37.2B | 65.8B | 57% |
| Total Cash | 12B | N/A | - |
| Total Debt | 57.3B | 49.1B | 117% |
AMGN | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 44 | |
SMR RATING 1..100 | 12 | 47 | |
PRICE GROWTH RATING 1..100 | 13 | 21 | |
P/E GROWTH RATING 1..100 | 41 | 2 | |
SEASONALITY SCORE 1..100 | n/a | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is in the same range as MRK (20) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
AMGN's Profit vs Risk Rating (13) in the Biotechnology industry is in the same range as MRK (44) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for MRK (47) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than MRK’s over the last 12 months.
AMGN's Price Growth Rating (13) in the Biotechnology industry is in the same range as MRK (21) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (41) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | MRK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 58% | 8 days ago 40% |
| Stochastic ODDS (%) | 4 days ago 45% | 4 days ago 66% |
| Momentum ODDS (%) | 4 days ago 66% | 4 days ago 49% |
| MACD ODDS (%) | 4 days ago 66% | 4 days ago 58% |
| TrendWeek ODDS (%) | 4 days ago 61% | 4 days ago 50% |
| TrendMonth ODDS (%) | 4 days ago 59% | 4 days ago 56% |
| Advances ODDS (%) | 6 days ago 59% | 4 days ago 56% |
| Declines ODDS (%) | 8 days ago 50% | 12 days ago 51% |
| BollingerBands ODDS (%) | 4 days ago 49% | N/A |
| Aroon ODDS (%) | 4 days ago 54% | 4 days ago 64% |
Advertisement